Amoxicillin+[clavulanic acid] in the treatment of lower respiratory tract infections

A.I. Sinopalnikov, I.A. Guchev

1) Russian Medical Academy of Continuous Professional Education, Moscow, Russia; 2) Nikita & Co LLC, Moscow, Russia

Amoxicillin+clavulanic acid is an inhibitor-protected aminopenicillin that has been widely used for over 40 years to treat community-acquired lower respiratory tract infections. The drug is effective against the main pathogens of community-acquired pneumonia (CAP) and exacerbations of chronic obstructive pulmonary disease (COPD), including Streptococcus pneumoniae, Haemophilus influenzae, and others. Despite the growing resistance of some strains, the use of increased doses of amoxicillin with clavulanic acid allows overcoming some types of resistance, providing high efficacy with good tolerability. Amoxicillin+clavulanic acid is a drug of choice for the treatment of respiratory infections, including CAP, exacerbations of COPD and chronic bronchitis, as well as bacterial upper respiratory tract infections.

Keywords

About the Authors

Alexander I. Sinopalnikov, Dr. Sci. (Med.), Professor, Head of the Department of Pulmonology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; aisyn@list.ru, ORCID: https://orcid.org/0000-0002-1990-2042
Igor A. Guchev, Cand. Sci. (Med.), pulmonologist, Nikita & Co LLC, Moscow, Russia; dr@igor-guchev.ru (corresponding author)

Similar Articles